Título:	Direct from the COVID-19 crisis : research and innovation sparks in Brazil
Autor(es):	Rosa, Mário Fabrício Fleury Silva, Everton Nunes da Pacheco, Christina Diógenes, Marcos Vinícius Pereira Millett, Christopher Gadelha, Carlos Augusto Grabois Santos, Leonor Maria Pacheco
ORCID:	https://orcid.org/0000-0002-4821-9007
Assunto:	Covid-19 - Brasil Pesquisa e desenvolvimento Saúde
Data de publicação:	21-Jan-2021
Editora:	BMC
Referência:	ROSA, Mário Fabrício Fleury et al. Direct from the COVID-19 crisis: research and innovation sparks in Brazil. Health Research Policy and Systems, v. 19, art. n. 10, 21 jan. 2021. DOI: https://doi.org/10.1186/s12961-020-00674-x. Disponível em: https://health-policy-systems.biomedcentral.com/articles/10.1186/s12961-020-00674-x. Acesso em: 02 fev. 2021.
Abstract:	Background The coronavirus disease 2019 (COVID-19) pandemic has spread throughout more than 160 countries, infecting millions of people worldwide. To address this health emergency, countries have organized the flow of production and innovation to reduce the impact on health. This article shows the response of the Brazilian scientific community to meet the urgent needs of the public unified health system [SUS], aiming to guarantee universal access to an estimated population of 211 million. By December 2020, Brazil had recorded more than six million cases and approximately 175,000 deaths. Methods We collected data on research, development and innovation projects carried out by 114 public universities (plus Oswaldo Cruz Foundation [Fiocruz] and Butantan Institute), as reported on their websites. Additionally, we examined the studies on COVID-19 approved by the National Comission for Research Ethics, as well as those reported on the Ministry of Education website as of May 15, 2020. Results The 789 identified projects were classified according to research categories as follows: development and innovation (n = 280), other types of projects (n = 226), epidemiologic research (n = 211), and basic research on disease mechanisms (n = 72). Most proposals focused on the development and innovation of personal protective equipment, medical devices, diagnostic tests, medicines and vaccines, which were rapidly identified as research priorities by the scientific community. Some promising results have been observed from phase III vaccine trials, one of which is conducted in partnership with Oxford University and another of which is performed with Sinovac Biotech. Both trials involve thousands of volunteers in their Brazilian arms and include technology transfer agreements with Fiocruz and the Butantan Institute, respectively. These vaccines proved to be safe and effective and were immediately licensed for emergency use. The provision of doses for the public health system, and vaccination, started on January 17, 2021. Conclusions The mobilized Brazilian scientific community has generated comprehensive research, development and innovation proposals to meet the most urgent needs. It is important to emphasize that this response was only possible due to decades of investment in research, development and innovation in Brazil. We need to reinforce and protect the Brazilian science, technology and innovation system from austerity policies that disregard health and knowledge as crucial investments for Brazilian society, in line with the constitutional right of universal health access and universal health coverage.
Unidade Acadêmica:	Faculdade UnB Ceilândia (FCE)
Programa de pós-graduação:	Programa de Pós-Graduação em Ciências e Tecnologias em Saúde
Licença:	© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativeco mmons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
DOI:	https://doi.org/10.1186/s12961-020-00674-x
Aparece nas coleções:	Artigos publicados em periódicos e afins UnB - Covid-19

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.